Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) EBIT Margin (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed EBIT Margin for 16 consecutive years, with 30.08% as the latest value for Q1 2026.

  • For Q1 2026, EBIT Margin fell 3225.0% year-over-year to 30.08%; the TTM value through Mar 2026 reached 1.07%, down 1724.0%, while the annual FY2025 figure was 5.88%, 1440.0% down from the prior year.
  • EBIT Margin hit 30.08% in Q1 2026 for Corcept Therapeutics, down from 2.22% in the prior quarter.
  • Across five years, EBIT Margin topped out at 31.39% in Q3 2022 and bottomed at 30.08% in Q1 2026.
  • Average EBIT Margin over 5 years is 16.13%, with a median of 21.73% recorded in 2024.
  • Year-over-year, EBIT Margin skyrocketed 604bps in 2024 and then crashed -3225bps in 2026.
  • Corcept Therapeutics' EBIT Margin stood at 21.83% in 2022, then grew by 7bps to 23.39% in 2023, then crashed by -41bps to 13.89% in 2024, then crashed by -84bps to 2.22% in 2025, then plummeted by -1455bps to 30.08% in 2026.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 30.08%, 2.22%, and 4.92% for Q1 2026, Q4 2025, and Q3 2025 respectively.